MedPage Today on MSN
FDA Proposes More Flexibility in Alternatives to Animal Testing in Drug Development
Non-animal testing methods could save drugmakers time and money, officials say ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency is recalibrating its evidentiary standards to align wit ...
The ambitious task on hand is apparent from the weighty title of the report – ‘Landscape Analysis on Alternatives to Animal Testing for Drug Development in India.’ That the report has the foreword by ...
In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...
One of the recurring themes in this column over the past few years has been the development of new test methods for sandwich composites. This is primarily a result of the opportunities I’ve had to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results